BioSyntech, Inc. (BSYI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioSyntech, Inc. (BSYI) with AI Score 50/100 (Hold). BioSyntech, Inc. is a Canadian biotechnology company focused on developing biotherapeutic thermogels for tissue repair and therapeutic delivery. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026BioSyntech, Inc. (BSYI) Healthcare & Pipeline Overview
BioSyntech, Inc., a Canadian biotechnology firm, specializes in biotherapeutic thermogels for tissue repair and targeted therapeutic delivery, with a focus on cartilage, bone, and wound healing applications. Currently in reorganization after a 2010 bankruptcy filing, the company's future hinges on successful product development and regulatory approvals within the competitive biotechnology landscape.
Investment Thesis
Investing in BioSyntech, Inc. presents a high-risk, high-reward scenario due to the company's current reorganization status following a 2010 bankruptcy filing. Key value drivers hinge on the successful development and commercialization of its biotherapeutic thermogels, particularly BST-CarGel for cartilage repair. The company's gross margin of 60.8% indicates potential profitability if products reach the market. However, the negative P/E ratio and a profit margin of -31739.1% reflect significant financial challenges. Growth catalysts include positive clinical trial results and regulatory approvals for its pipeline products. Potential risks include the ongoing reorganization process, competition from established biotechnology companies, and the need for substantial additional funding to support research and development. Investors should carefully consider these factors before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross margin of 60.8% suggests potential for profitability upon successful commercialization of products.
- The company is currently in reorganization after filing for administration under the Bankruptcy and Insolvency Act in 2010, indicating financial distress.
- Lead product BST-CarGel targets a significant market for cartilage repair, offering potential for revenue generation if approved.
- Negative P/E ratio indicates the company is currently not profitable.
- Profit Margin of -31739.1% reflects substantial losses and operational challenges.
Competitors & Peers
Strengths
- Proprietary thermogel technology platform.
- Potential for targeted therapeutic delivery.
- Focus on unmet needs in tissue repair.
- Manufacturing capabilities for ultra-pure chitosans.
Weaknesses
- Currently in reorganization after bankruptcy filing.
- Limited financial resources.
- Dependence on successful clinical trials and regulatory approvals.
- Small market capitalization.
Catalysts
- Upcoming: Positive results from clinical trials of BST-CarGel for cartilage repair.
- Upcoming: Regulatory approval of BST-CarGel by health authorities.
- Upcoming: Successful restructuring and emergence from bankruptcy reorganization.
- Ongoing: Development and advancement of other pipeline products (BST-InPod, BST-DermOn, etc.).
- Ongoing: Potential partnerships with larger pharmaceutical or medical device companies.
Risks
- Ongoing: Financial instability due to bankruptcy reorganization.
- Potential: Failure to obtain regulatory approvals for its products.
- Potential: Competition from established biotechnology companies.
- Potential: Inability to secure additional funding for research and development.
- Potential: Patent expiration and loss of intellectual property protection.
Growth Opportunities
- BST-CarGel for Cartilage Repair: The market for cartilage repair is substantial, driven by the prevalence of osteoarthritis and sports-related injuries. BST-CarGel, a biodegradable gel, offers a potential solution for repairing damaged cartilage. Successful clinical trials and regulatory approval could lead to significant revenue generation. The timeline for commercialization depends on the progress of clinical trials and regulatory review processes. Competition includes existing surgical procedures and other regenerative medicine approaches. Market size estimates for cartilage repair range from $2 billion to $4 billion annually.
- BST-InPod for Heel Pain Relief: Heel pain, often caused by plantar fasciitis, affects a significant portion of the population. BST-InPod aims to provide relief through targeted therapeutic delivery. The market for heel pain treatments includes orthotics, physical therapy, and pain medication. BST-InPod's potential lies in offering a more effective and convenient solution. Market research indicates a growing demand for non-surgical heel pain treatments. The timeline for commercialization depends on product development and clinical testing. The global market for pain management is estimated to reach $83 billion by 2027.
- BST-DermOn for Chronic Wound Healing: Chronic wounds, such as diabetic ulcers and pressure sores, represent a significant healthcare burden. BST-DermOn is designed to promote wound healing through its thermogel technology. The market for wound care products is expanding, driven by an aging population and the increasing prevalence of diabetes. BST-DermOn's success depends on its ability to demonstrate superior efficacy compared to existing wound care treatments. The global wound care market is projected to reach $22 billion by 2028. Clinical trials and regulatory approvals are key milestones for commercialization.
- BST-Ossifil and BST-Ossifix for Bone Repair: Bone defects and fractures are common orthopedic problems. BST-Ossifil and BST-Ossifix are designed to address these issues by providing bone filling and structural support. The market for bone repair products includes bone grafts, synthetic bone substitutes, and fixation devices. BioSyntech's thermogel technology offers a potential advantage in terms of biocompatibility and ease of use. The global bone graft and substitutes market is projected to reach $3.7 billion by 2027. Regulatory approvals and clinical data will be crucial for market adoption.
- BST-Disc for Intervertebral Disc Restoration: Intervertebral disc degeneration is a major cause of back pain. BST-Disc aims to restore disc function through its thermogel technology. The market for spine surgery and pain management is substantial. BST-Disc's potential lies in offering a less invasive alternative to traditional spinal fusion procedures. The global spine surgery market is projected to reach $17.8 billion by 2028. Clinical trials and regulatory approvals are essential for commercialization. Competition includes established medical device companies and other regenerative medicine approaches.
Opportunities
- Growing market for tissue repair and regenerative medicine.
- Potential partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
- Increasing demand for minimally invasive treatments.
Threats
- Competition from established biotechnology companies.
- Regulatory hurdles and delays.
- Patent expiration and biosimilar competition.
- Economic downturn and reduced healthcare spending.
Competitive Advantages
- Proprietary thermogel technology platform.
- Patents protecting its product formulations and applications.
- Potential for strong clinical data supporting product efficacy.
- Expertise in chitosan manufacturing and biotherapeutic delivery.
About BSYI
BioSyntech, Inc., incorporated in 1994 and based in Laval, Canada, is a biotechnology company dedicated to the development of biotherapeutic thermogels. These thermogels are designed for tissue repair and the targeted delivery of therapeutics. The company's primary focus is on addressing unmet needs in areas such as cartilage repair, bone regeneration, and wound healing. Its lead product, BST-CarGel, is a biodegradable gel intended for cartilage repair. Other products in development include BST-InPod for heel pain relief, BST-DermOn for chronic wound healing, BST-Ossifil for bone filling, BST-Ossifix for bone structural support, and BST-Disc for intervertebral disc restoration. BioSyntech's product portfolio also includes BST-Gel-based injectable products for targeted biotherapeutic delivery, Arthro-BST, an arthroscopic device for cartilage evaluation, and Mach-1, a micromechanical testing system. Additionally, the company manufactures ultra-pure chitosans under the Ultrasan name and provides manufacturing and analytical services. However, BioSyntech filed for administration under the Bankruptcy and Insolvency Act on May 12, 2010, and is currently in reorganization, presenting significant challenges to its operations and future prospects. The company's ability to successfully navigate this reorganization and advance its product pipeline will be critical to its long-term viability.
What They Do
- Develops biotherapeutic thermogels for tissue repair.
- Focuses on cartilage, bone, and wound healing applications.
- Creates injectable products for targeted biotherapeutic delivery.
- Manufactures ultra-pure chitosans under the Ultrasan name.
- Offers manufacturing and analytical services.
- Develops arthroscopic devices for cartilage evaluation.
- Creates micromechanical testing systems for evaluating tissue properties.
Business Model
- Develops and patents biotherapeutic thermogel technologies.
- Seeks regulatory approval for its products.
- Aims to commercialize its products through partnerships or direct sales.
- Generates revenue through product sales and manufacturing services.
Industry Context
BioSyntech operates within the competitive biotechnology industry, which is characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The market for tissue repair and therapeutic delivery is growing, driven by an aging population and increasing demand for minimally invasive treatments. Competitors include companies developing regenerative medicine therapies and advanced biomaterials. BioSyntech's success depends on its ability to differentiate its thermogel technology, secure regulatory approvals, and establish partnerships for commercialization. The industry is also subject to evolving regulatory landscapes and pricing pressures.
Key Customers
- Hospitals and clinics specializing in orthopedics.
- Surgeons performing cartilage repair and bone regeneration procedures.
- Wound care centers and specialists.
- Research institutions and pharmaceutical companies utilizing chitosan.
Financials
Chart & Info
BioSyntech, Inc. (BSYI) stock price: Price data unavailable
Latest News
No recent news available for BSYI.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BSYI.
Price Targets
Wall Street price target analysis for BSYI.
MoonshotScore
What does this score mean?
The MoonshotScore rates BSYI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Amine Selmani
CEO
Amine Selmani serves as the CEO of BioSyntech, Inc. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Further research would be required to provide a comprehensive background profile. His expertise and leadership are crucial for guiding the company through its current reorganization phase and advancing its product pipeline.
Track Record: Due to the limited information available, it is not possible to assess Amine Selmani's track record at BioSyntech, Inc. or his previous accomplishments. Further research is needed to determine his key achievements, strategic decisions, and the company's milestones under his leadership. The impact of his leadership on the company's reorganization efforts remains unknown.
BSYI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BioSyntech may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and speculative investments due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher potential for fraud and manipulation.
- Significant price volatility due to low trading volume.
- Risk of delisting and loss of investment.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Evaluate the company's capitalization structure and potential dilution.
- Check for any red flags or warning signs, such as pending lawsuits or regulatory investigations.
- Longevity of operations (incorporated in 1994).
- Development of multiple products in the biotherapeutics space.
- Manufacturing capabilities for ultra-pure chitosans.
- Patents protecting its product formulations and applications.
What Investors Ask About BioSyntech, Inc. (BSYI)
What does BioSyntech, Inc. do?
BioSyntech, Inc. is a biotechnology company focused on developing biotherapeutic thermogels for tissue repair and therapeutic delivery. Their primary focus is on products like BST-CarGel for cartilage repair, BST-InPod for heel pain, and BST-DermOn for chronic wound healing. They also manufacture ultra-pure chitosans. However, the company is currently in reorganization after filing for administration under the Bankruptcy and Insolvency Act in 2010, which presents significant challenges to its operations and future prospects.
What do analysts say about BSYI stock?
As of 2026-03-16, formal analyst ratings are unavailable for BSYI stock, likely due to its OTC listing and reorganization status. Key valuation metrics such as P/E ratio (-0.00) and profit margin (-31739.1%) indicate significant financial challenges. Growth considerations hinge on successful product development, regulatory approvals, and emergence from bankruptcy. Investors should conduct thorough due diligence and consider the high-risk nature of this investment.
What are the main risks for BSYI?
The main risks for BioSyntech, Inc. include its ongoing reorganization after a 2010 bankruptcy filing, which creates financial instability and uncertainty. The company faces potential challenges in obtaining regulatory approvals for its products and competition from larger, more established biotechnology firms. Additionally, the company's ability to secure additional funding for research and development is crucial for its long-term survival. Patent expiration and loss of intellectual property protection also pose a threat.
What are the key factors to evaluate for BSYI?
BioSyntech, Inc. (BSYI) currently holds an AI score of 50/100, indicating moderate score. Key strength: Proprietary thermogel technology platform.. Primary risk to monitor: Ongoing: Financial instability due to bankruptcy reorganization.. This is not financial advice.
How frequently does BSYI data refresh on this page?
BSYI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BSYI's recent stock price performance?
Recent price movement in BioSyntech, Inc. (BSYI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary thermogel technology platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BSYI overvalued or undervalued right now?
Determining whether BioSyntech, Inc. (BSYI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BSYI?
Before investing in BioSyntech, Inc. (BSYI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC status and reorganization.
- AI analysis is pending and may provide further insights.